Herbacos-Bofarma
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Herbacos-Bofarma - overview
Established
1991
Location
-, -, Czech Republic
Primary Industry
Consumer Products
About
Herbacos-Bofarma is a Czech company dedicated to the formulation and distribution of herbal and pharmaceutical products, focusing on natural health solutions through phytotherapy and dietary supplements. Founded in 1991 in the Czech Republic, Herbacos-Bofarma specializes in creating herbal and pharmaceutical products. The company was sold to Recordati S. p.
A. in January 2009, which marked a significant pivot in its business operations. It has since operated under the umbrella of Recordati, expanding its product offerings and market reach. Herbacos Recordati s.
r. o. specializes in the formulation and distribution of herbal and pharmaceutical products, leveraging their expertise in phytotherapy and the development of medicinal and dietary supplements. The company's core offerings include a range of herbal extracts, essential oils, and various formulations aimed at addressing health concerns such as digestive issues, respiratory ailments, and overall wellness.
These products are designed for both individual consumers and healthcare professionals, providing solutions that cater to specific health needs while promoting natural approaches to treatment. Herbacos Recordati's products are sold primarily in the European markets, where they have established a strong presence among pharmacies, health food stores, and online retailers, thereby reaching a diverse clientele that includes health-conscious consumers and healthcare providers. In the most recent year, 2023, Herbacos Recordati reported a revenue of USD 42. 39 mn and an EBITDA of USD 487,835.
9. Herbacos-Bofarma plans to expand its product line with several new herbal formulations targeting specific health needs, expected to launch by late 2024. The company is also planning to enter new markets, particularly in Central and Eastern Europe, by 2025. Funding from the sale to Recordati S.
p. A. will be utilized to support these initiatives, enhancing research and development capabilities and increasing market penetration.
Primary Industry
Consumer Products
Sub Industries
Beauty & Hygiene, Drug Stores/Convenience Stores
Website
www.recordati.cz
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Herbacos-Bofarma - timeline of key events
Herbacos-Bofarma - financials
| Fiscal Year Ended | Dec 31, 2009 | Dec 31, 2010 | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 321,652,000 | 306,447,000 | - | 374,845,000 | 349,765,000 | 353,327,000 | 339,361,000 | 356,819,000 | 438,400,000 | 649,116,000 | 681,267,000 | 762,212,000 | 693,366,000 | 840,326,000 | - | - | - |
| % Revenue Growth (YoY) | - | (4.7%) | - | - | (6.7%) | 1.0% | (4.0%) | 5.1% | 22.9% | 48.1% | 5.0% | 11.9% | (9.0%) | 21.2% | - | - | - |
| EBITDA (USD) | 55,137,000 | 61,828,000 | - | 99,078,000 | 75,460,000 | 77,567,000 | 62,411,000 | 69,322,000 | 78,715,000 | 72,478,000 | 98,771,000 | 110,092,000 | 9,869,000 | 67,991,000 | - | - | - |
| Operating Income (USD) | 17,671,000 | 25,745,000 | - | 95,212,000 | 70,859,000 | 71,420,000 | 56,110,000 | 63,034,000 | 72,307,000 | 65,999,000 | 92,382,000 | 103,102,000 | 2,447,000 | 59,827,000 | - | - | - |
| Operating Margin | 5.5% | 8.4% | - | 25.4% | 20.3% | 20.2% | 16.5% | 17.7% | 16.5% | 10.2% | 13.6% | 13.5% | 0.4% | 7.1% | - | - | - |
| % EBITDA Margin | 17.1% | 20.2% | - | 26.4% | 21.6% | 22.0% | 18.4% | 19.4% | 18.0% | 11.2% | 14.5% | 14.4% | 1.4% | 8.1% | - | - | - |
| NET Income (USD) | 12,014,000 | 18,590,000 | - | 77,298,000 | 58,693,000 | 57,845,000 | 44,107,000 | 50,752,000 | 55,766,000 | 51,272,000 | 71,495,000 | 84,943,000 | (1,153,000) | 44,050,000 | - | - | - |
| % Net Margin | 3.7% | 6.1% | - | 20.6% | 16.8% | 16.4% | 13.0% | 14.2% | 12.7% | 7.9% | 10.5% | 11.1% | (0.2%) | 5.2% | - | - | - |
Herbacos-Bofarma - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Herbacos-Bofarma | - | ||||||||
| Buyout | Completed | Herbacos-Bofarma | - |
Displaying 1 - 2 of 2
Herbacos-Bofarma - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.